IBT Receives an SBIR from NIAID for development of a post-exposure vaccine for Streptococcus pneumoniae
A Novel approach to fight pneumonia
IBT receives an SBIR grant from NIH, entitled Serotype independent therapeutic vaccine for Streptococcus pneumoniae.
Antibiotic-resistant bacterial pathogens represent a major challenge within the community, healthcare settings, as well as the military. The growing incidence of bacterial pathogens signals the emergence of the so called “post-antibiotic era”. Vaccines exist only for Antibiotic-resistant bacterial pathogens. Innovative concepts are needed to face these serious challenges of the 21st century.
Under this NIAID SBIR grant IBT, in collaboration with Dr. Daniel Nelson Laboratory at University of Maryland, seeks to develop a novel technology, i.e. an Infection Site Targeted universal Bridging Antigen (ISTuBA) that builds an immunological bridge between a new invading pathogen and a pre-existing, heterologous immune response that is prevalent within the population. The prototype ISTuBA will be created for Streptococcus pneumoniae, a leading cause of pneumonia, sepsis and meningitis worldwide.
The SBIR grant will fund IBT and University of Maryland to develop the first ISTuBA prototype and demonstrate its efficacy against S. pneumoniae in mouse models of pneumonia. Upon completion of this proof of concept IBT expects to transition the program into advanced preclinical development under a Phase II SBIR.